- Home
- LBRX vs EMD Comparison
LBRX vs EMD Comparison
Compare LBRX & EMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LBRX | EMD |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.2M | 613.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LBRX | EMD |
|---|---|---|
| Price | $19.89 | $10.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 531.1K | 248.5K |
| Earning Date | 02-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $7.85 |
| 52 Week High | $23.15 | $9.55 |
Technical Indicators
Market Signals| Indicator | LBRX | EMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.25 |
| Support Level | N/A | $10.66 |
| Resistance Level | N/A | $10.93 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 54.69 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.